BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference

BioXcel Therapeutics, a biopharmaceutical company, announced that Vimal Mehta, CEO, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. To access the webcast, visit the company's website at bioxceltherapeutics.com. A replay will be available for 90 days.

BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, has announced that its CEO, Vimal Mehta, Ph.D., will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The event will take place on August 12, 2025, at 12 p.m. ET in Boston [1]. Investors and financial professionals can access the webcast through the company's website under the "Events & Presentations" page, with a replay available for 90 days [2].

BioXcel Therapeutics focuses on re-innovating existing drugs and clinically validated product candidates using big data and proprietary machine learning algorithms to identify new therapeutic indications. The company's wholly owned subsidiary, OnkosXcel Therapeutics, is dedicated to developing medicines in the immuno-oncology field [1].

This announcement comes as part of BioXcel Therapeutics' ongoing efforts to engage with the investment community and provide updates on its progress in neuroscience drug development. The fireside chat is expected to offer insights into the company's strategic vision, recent advancements, and future plans.

For more information about BioXcel Therapeutics, please visit their official website at [BioXcel Therapeutics](https://www.bioxceltherapeutics.com).

References:
[1] https://finance.yahoo.com/news/bioxcel-therapeutics-participate-canaccord-genuity-110000181.html
[2] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-participate-in-canaccord-genuity-45th-ijfsv8m1ht4x.html